Table 4. Gains to GDP due to adolescent/adult TB vaccines across 2028–2080 for 105 analyzed LMICs by vaccine characteristic and delivery scenario.

Scenario	Absolute gains in GDP (billions 2020 US dollars)	Percentage gain in GDP (%)
Base–case	1,618 (764, 2,988)	0.0326% (0.0266%, 0.0388%)
Lifelong duration of protection	2,518 (1,140, 4,789)	0.0484% (0.0403%, 0.0572%)
75% vaccine efficacy	2,355 (1,069, 4,387)	0.0452% (0.0377%, 0.0530%)
Low coverage	1,205 (527, 2,289)	0.0231% (0.0188%, 0.0276%)
High coverage	1,912 (843, 3,606)	0.0366% (0.0301%, 0.0436%)
Accelerated scale-up	2,765 (1,241, 5,229)	0.0532% (0.0445%, 0.0621%)
Routine delivery-only	352 (139, 710)	0.0067% (0.0049%, 0.0086%)
Rapid TB decline	55 (−77.6, 272)	0.0008% (−0.0022%, 0.0039%)

Note: Values in parentheses represent equal-tailed 95% uncertainty intervals.

GDP, gross domestic product; LMIC, low- and middle-income country; TB, tuberculosis.